clindamycin and benzoyl peroxide kit
remedyrepack inc. - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c) - clindamycin and benzoyl peroxide topical gel, 1%/5% is indicated for the topical treatment of acne vulgaris. clindamycin and benzoyl peroxide topical gel, 1%/5% is contraindicated in those individuals who have shown hypersensitivity to any of its components or to lincomycin. it is also contraindicated in those having a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.
clindamycin phosphate and benzoyl peroxide gel
oceanside pharmaceuticals - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c), benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - clindamycin phosphate and benzoyl peroxide gel, 1.2%/3.75% is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. clindamycin phosphate and benzoyl peroxide gel is contraindicated in those individuals who have shown hypersensitivity to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. anaphylaxis, as well as allergic reactions leading to hospitalization, has been reported in postmarketing use with clindamycin phosphate and benzoyl peroxide gel [see postmarketing experience (6.2)] . clindamycin phosphate and benzoyl peroxide gel is contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis [see warnings and precautions (5.1)] . risk summary there are no available data on clindamycin phosphate and benzoyl peroxide gel use in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. the limited published data on use
adapalene 0.3% / benzoyl peroxide 2.5% / clindamycin 1% gel
sincerus florida, llc - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c), adapalene (unii: 1l4806j2qf) (adapalene - unii:1l4806j2qf), benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) -
adapalene 0.1% / benzoyl peroxide 2.5% / clindamycin 1% gel
sincerus florida, llc - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c), adapalene (unii: 1l4806j2qf) (adapalene - unii:1l4806j2qf), benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) -
clindamycin phosphate and benzoyl peroxide- clindamycin phosphate, benzoyl peroxide gel
bryant ranch prepack - benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm), clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c) - clindamycin phosphate and benzoyl peroxide gel, 1.2%/2.5% is indicated for the topical treatment of acne vulgaris in patients 12 years or older. clindamycin phosphate and benzoyl peroxide gel, 1.2%/2.5% is contraindicated in those individuals who have shown hypersensitivity to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. anaphylaxis, as well as allergic reactions leading to hospitalization, has been reported in postmarketing use with clindamycin phosphate and benzoyl peroxide gel, 1.2%/2.5%. [see postmarketing experience (6.2). ] clindamycin phosphate and benzoyl peroxide gel, 1.2%/2.5% is contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis. [see warnings and precautions (5.1). ] risk summary there are no available data on clindamycin phosphate and benzoyl peroxide gel, 1.2%/2.5% use in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome
clindamycin and benzoyl peroxide gel
remedyrepack inc. - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c), benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - clindamycin and benzoyl peroxide gel is indicated for the topical treatment of acne vulgaris. clindamycin and benzoyl peroxide gel is contraindicated in those individuals who have shown hypersensitivity to any of its components or to lincomycin. it is also contraindicated in those having a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.
duac once daily gel
glaxosmithkline nz limited - benzoyl peroxide 66.7 mg/g; clindamycin phosphate 12.8 mg/g; - topical gel - 1%w/w, 5%w/w - active: benzoyl peroxide 66.7 mg/g clindamycin phosphate 12.8 mg/g excipient: carbomer 940 colloidal silicon dioxide dimeticone disodium edetate dihydrate disodium lauryl sulfosuccinate glycerol poloxamer purified water sodium hydroxide - for the topical treatment of comedo, papular and pustular acne vulgaris.
duac once daily 10mg/g + 50mg/g gel
glaxosmithkline (ireland) limited - clindamycin phosphate; benzoyl peroxide hydrous - gel - 10mg/g + 50 milligram(s)/gram - antiinfectives for treatment of acne; clindamycin, combinations
duac once daily 10mg/g + 30mg/g gel
glaxo smithkline uk limited - benzoyl peroxide; clindamycin - gel - benzoyl peroxide 30 mg/g; clindamycin 10 mg/g - anti-acne preparations
acanya- clindamycin phosphate and benzoyl peroxide gel
bausch health us, llc - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c), benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - clindamycin 10 mg in 1 g - acanya® gel is indicated for the topical treatment of acne vulgaris in patients 12 years or older. acanya gel is contraindicated in those individuals who have shown hypersensitivity to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. anaphylaxis, as well as allergic reactions leading to hospitalization, has been reported in postmarketing use with acanya gel [see postmarketing experience (6.2)] . acanya gel is contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis [see warnings and precautions (5.1)] . risk summary there are no available data on acanya gel use in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. the limited published data on use of clindamycin in pregnant women with exposure during the first trimester are insufficient to inform a drug-associated risk of pregnancy-related adverse outcomes (see data) .in limited published cli